From lab to factory floor: ChemT nets US$4M to make cell therapies easier to manufacture
Summary
ChemT Biotechnology, a US‑Singapore startup that claims it has built an “intelligence layer” for bio-manufacturing, has raised a total of US$5 million in 18 months, including a US$4 million seed round led by Wavemaker Ventures and co‑investment partner SEEDS. The company, which combines machine learning models with wet‑lab validation, argues its tools can shorten development […] The post From lab to factory floor: ChemT nets US$4M to make cell therapies easier to manufacture appeared first on e27 .
Why It Matters
This Biotech development strengthens the region's biomanufacturing and life-sciences base. For Singapore, it is a signal worth tracking: it shapes who supplies, who scales, and who sets the standard over the next five years.
Key Facts
- SectorBiotech
- MarketSingapore
- ImpactMedium (52/100)
- SignalFunding